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Abstract:  Background: The bur-
den of tuberculosis is high in Nige-
ria as in other developing coun-
tries. The administration of BCG 
vaccine to neonates is essential in 
the control of tuberculosis. A scar 
usually develops 6 – 8 weeks later 
at the site of vaccination, which 
can be used clinically as a proof of 
vaccination. Not all vaccinated 
infants however, develop a BCG 
scar. 
Objectives: To determine the 
prevalence of scar formation post-
vaccination and to unravel, if pre-
sent, any factors responsible for 
scar failure. 
Methods: Two hundred and four-
teen children were consecutively 
recruited from those who presented 
for immunization in the University 
of Benin Teaching Hospital, Benin. 
The bio-data and other relevant 
information were obtained using a 
proforma. The anthropometric 
measurements of the children were 
obtained and the children were 
examined for presence of a BCG 
scar. 
Results: Two hundred and six sub-
jects (96.3%) had a post-
vaccination BCG scar. About 72% 
of the subjects were vaccinated 
within the first week of life. The 
age at vaccination was signifi-
cantly affected by gestational 
maturation (P=0.003) and birth 
weight (P=0.0001). Gestational 
maturation is a strong predictor of 
BCG scar formation post-
vaccination (P = 0.007) 
Conclusion: There is high preva-
lence of BCG scar formation in 
this study and gestational matura-
tion is a strong predictor of BCG 
scar formation.  
Introduction 
 
Tuberculosis is an infectious disease which is prevalent 
in developing countries. In 2011, there were an esti-
mated 8.7million new cases of Tuberculosis in the gen-
eral population (13% co-infected with HIV) and 
1.4million people died from the disease1.  There were an 
estimated 0.5million cases and 64000 deaths among 
children in 2011.Africa and Asia have the highest bur-
den of tuberculosis1. The African Region has approxi-
mately one-quarter of the world’s cases, and the highest 
rates of cases and deaths relative to population. Nigeria 
is one of the 22 countries with a high burden of tubercu-
losis, with an incidence of about between 90,000 to 
330,000 cases per year1. 
 
As part of control measures to reduce the burden of tu-
berculosis especially in children, the World Health Or-
ganization recommends vaccination with BacilleCal-
mette-Guerin vaccine at birth or first contact with health 
services, especially in developing countries.2 The World 
Health Organization has emphasized this policy in re-
cent years, because of consistent evidence that BCG 
protects against serious childhood forms of tuberculosis, 
even where it may not protect to a high degree against 
adult pulmonary form of the disease2. In various clinical 
trials the estimates of effectiveness have ranged from 
80% protection to no benefit3. Despite its limitations, the 
BCG vaccine is the only currently available vaccine for 
the prevention of tuberculosis. Overall, more than 80% 
of all neonates and infants in countries where the vac-
cine is part of the national childhood immunization pro-
rammereceive the vaccine4. The coverage however, 
varies from country to country. The estimated BCG cov-
erage for the year 2011, reported by the World Health 
Organization, revealed levels ranging from 54% in 
Ethiopia and 60% in Nigeria, to 99.5% in India and  
China5. 
 
The BaccilleCalmette-Guerin contains a live attenuated 
strain of Mycobacterium bovis which is administered 
intra-dermally over the left deltoid muscle. After a  
period of 6 – 8 weeks post-vaccination a swelling  
appears which increases in size and ruptures leaving 
behind a life-long puckered scar after healing. Thepres-
ence of a BCG scar and the tuberculin skin test are util-
ized in clinical settings to determine those who have 
been immunized with the BCG vaccine. The tuberculin 
skin test is usually positive in people who have received 
the vaccine. Considering the fact that the tuberculin test 
is also positive in those with the disease and those ex-
posed to non-tuberculous mycobacteria infection, it is 
not specific for identifying those who have received the 
vaccine. Moreover, the result is often negative in im-
munocompromised (HIV, disseminated tuberculosis, 
malignant conditions) individuals, even those who had 
previously been vaccinated, due to cutaneous anergy.  
 
In the absence of a vaccination card the BCG scar may 
thus be the only option left to clinically determine vacci-
nation status. It is however, noted that not all vaccinated 
children develop a scar.6Different studies world-wide 
have reported varying prevalence rates of the presenc  
of BCG scar in vaccinated children.  A study in Karachi, 
involving 250 infants, reported presence of scar in 
80.4% of the infants.6However in this study, the age at 
vaccination, gestational age and other characteristics of 
the children were not evaluated in order to find the pos-
sible reason for the absence of scar formation. A study 
in Northern Nigeria reported a 95.1% prevalence of scar 
formation.7This study however, evaluated only 41 chil-
dren. Another study in Northern Nigeria evaluated 296 
children between the ages of 3 – 59months receiving 
immunization in a Teaching Hospital and two Primary 
Health Centers. Only 55.7% of the vaccinated children 
had a BCG scar.8 This study is aimed at evaluating in-
fants in Southern Nigeria to determine the prevalence of 
scar formation and to unravel, if present, any factors hat 




Materials and method 
 
This is a cross-sectional study carried out between June 
and September, 2012 at the University of Benin Teach-
ing Hospital, Benin-city, Edo State. The Hospital offers 
curative and preventive services to patients from Edo 
State and the neighbouring States of Delta, Ondo, 
Bayelsa, Ekiti and Kogi. Immunization services take 
place in the General Practice Clinic and the Institute of 
Child Health, on a daily basis from Monday to Friday, 
except on public holidays. The immunization units of 
the General Practice Clinic and Institute of Child Health 
vaccinate about 1000 children respectively annually. 
Ethical clearance for the study was obtained from the 
Ethical Committee of the University of Benin Teaching 
Hospital. A verbal consent was obtained from the par-
ents and caregivers of the subjects after explaining the 
objectives and the harmless nature of the study.   
 
The subjects were consecutively recruited from children 
attending the General Practice Clinic, who had been 
previously vaccinated with BCG and have presently 
come for subsequent vaccines in the National Pro-
gramme on Immunization schedule.  Information on the 
bio data such as age, sex, and gestational age were ob-
tained using a proforma. Information on birth weight, 
age at receipt of BCG vaccine and place of vaccinatio  
were also obtained. Subjects delivered before 37 com-
pleted weeks of gestation from the mothers last men-
strual cycle were classified as preterm; those betwe n 37 
and 42 completed weeks of gestation as term while 
those delivered after 42 completed weeks were classified 
as post-term. The weight of the subjects was measurd 
with an infant weighing scale, Way masterR made in 
England, calibrated to the nearest 50gm; the length was 
assessed with an infantiometer while the head circumfer-
ence was measured with a non-elastic measuring tape.
The left upper arm around the deltoid was examined for 
presence of a BCG scar. The subjects were classified 
nutritionally using the WHO weight for age z-score 
growth charts. Subjects with z-score of less than –3 were 
classified as severely under-nourished; between –3 and –
2 as moderately under-nourished; between –2 and +2 as 
normal; while above+2 as overweight.9The data col-
lected was recorded in Microsoft Excel spreadsheet and 
transported to SPSS version 19 for analysis. Univariate 
analysis was conducted for all variables to assess their
distribution. Continuous variables were summarized 
using means and standard deviations while categorical 
variables were summarized using proportions.  
Chi-square test was used to determine association  
between categorical variables. P-value of less than0.05 





A total of two hundred and fourteen subjects comprising 
117 (54.7%) males and 97 (45.3%) females were re-
cruited for the study. The mean age of the subjects wa  
4.33 ± 2.54 months. The ages of the subjects ranged 
from 6weeks to 15months. The age group of 6weeks – 6 
months formed the bulk (90.7%) of the study popula-
tion. The general characteristics of the study population 
are as shown in table 1. 
 
Table 1: General characteristics of the study population 
Characteristic                                   n                       % 
Gender 
        Male                                   117                           54.7 
        Female                                97                         45.3 
Age (in months) 
       1.5 – 6                                  94                          90.7 
       7 – 12                                   16                          7.5 
       ≥13                                       4                             1.9 
Age at vaccination (days) 
       1 – 7                                     151                          71.9 
       8 – 14                                   35                          16.7 
       15 – 21                                 9                          4.3 
       22 – 28                                 3                          1.4 
       ≥ 29                                      12                            5.7 
 Gestational Maturation 
   Pre-term                                   15                         7.1 
      Term                                      186                         88.6 
      Post-term                               9                          4.3 
 Birth weight category 
    Low birth weight                    13                      7.6 
     Normal birth weight               137                    80.1 
     High birth weight                   21                       12.3 
 Place of vaccination 
    Private Hospitals                     21                      9.9 
    UBTH                                     180                       84.9 
    Other Public Hospitals            11                      5.2 
 Nutritional status 
    Overweight                              11                            5.2 
    Normal                                     190                         88.8 
    Underweight                             8                             3.7 
    Severe malnutrition                  5                       2.3 
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Majority of the subjects (71.9%) were vaccinated within 
the first week of life while 16.7% were vaccinated be-
tween the 8th and 14th day of life. Twelve (5.7%) sub-
jects were vaccinated after one month of life. Among 
those vaccinated within the first week of life 9.3% and 
10.6% were vaccinated on the 1st and 2nd day of life re-
spectively. Majority of them (44.4%) were vaccinated 
on the 7th day of life. A greater proportion (26.7%) of 
pre-term infants were vaccinated after 4weeks of age in 
comparison to the term (9.3%) and post-term (0%) sub-
jects as shown in table 2. This difference was statisti-
cally significant (P=0.003). Similarly, a greater pro or-
tion (30.8%) of the subjects with low birth weight were 
vaccinated after 4weeks in comparison to normal birth 
weight (0.7%) and high birth weight (4.8%) babies. This 
difference was also statistically significant (P=0.0001). 
The above findings indicate that prematurity and low 
birth weight are significantly associated with late pres-
entation of the study population for BCG vaccination. 
 
Table 2: Association between age of vaccination and 
gestational maturity and birth weight  
Pre-term          9(60)           2(13.3)      4(26.7) 
Term               165(90.7)    9(4.9)        8(4.4)        16.28    0.003 
Post term         9(100)         0(0)          0(0) 
Birth weight category 
LBW                7(53.8)       2(15.4)      4(30.8) 
NBW               130(94.9)   6(4.4)        1(0.7)         35.93  0.0001 
HBW               18(85.7)     2(9.5)        1(4.8) 
 
Evaluation of the nutritional status of the study popula-
tion, as shown in table 3, showed normal nutrition n 
190 (88.8%) subjects; 5.2% were overweight while 
2.3% had severe malnutrition. 
 
Presence of scar post-vaccination was observed in 206 
of the subjects, giving a prevalence of 96.3%. There was 
absence of scar in 8 (3.7%).Evaluation of the factors 
related to scar formation showed a statistically signifi-
cant difference (p = 0.011) among subjects in the vari-
ous gestational age groups as shown in table 3. Absent 
scar formation was highest among the post-term (22.2%) 
in comparison to the term (3.2%) and pre-term (0%) 
subjects. The presence of BCG scar was not signifi-
cantly associated with the place of vaccination; chrono-
logical age at vaccination, nutritional status, birth 
weight, and gender of the subjects.  
      Age at vaccination (days)                          χ2        P-value 
                        0 – 14        15 – 28      ≥29 
                        n(%)            n(%)       n(%) 
Gestational maturity 
Table 3: Association between BCG scar formation and some 
variables. 
Variables    Presence of scar    Absence of scar          P-value 
                           n(%)                    n(%)                    
Gender 
    Male                 110(94)             7(6)                      0.057 
   Female               96(99)               1(1) 
Gestational Maturity 
   Pre-term            15(100)              0(0) 
   Term                 180(96.8)           6(3.2)                  0.011     
   Post-term          7(77.8)               2(22.2) 
Age at vaccination (days) 
   1 – 14                180(96.8)           6(3.2) 
  15 – 28               11(91.7)             1(8.3)                   0.509 
  ≥29                     12(100)              0(0) 
Birth weight categories 
Normal                 134(95)             7(5) 
Low birth weight 13(100)              0 (0)                0.415 
High birth weight 21(100)             0(0) 
Place of vaccination 
  UBTH                 173(96.1)         7(3.9) 
  Other GovtHosp  10 (90.9)          1 (9.1)            0.619 
  Private Hospitals  21(100)           0(0) 
Nutritional status 
Over-weight          11(100)             0(0) 
Normal                  182(95.8)          8(4.2)                   0.789 
Underweight          8(100)              0(0) 






The WHO recommendations for routine use in EPI 
schedule and available data on BCG vaccine effectiv-
ness indicate that the vaccine should be administered as 
soon as possible after birth and before 1 month of age
for maximumprotection.11In this study, 71.9% of the 
subjects were vaccinated within the first week of life, 
while 5.7% were vaccinated after one month of age. 
Previous studies showed variable rates at reception of 
BCG vaccination. A study from Sri Lanka reported 99% 
reception of BCG within the first week of life12. The 
very high rate of vaccination within the first week of life 
in the Sri Lankan study may be due to high awareness of 
the need for BCG immunization which is reflected in the 
high BCG coverage of almost 100%11 as against 49.7% 
in Nigeria where this study was carried out.12A similar 
study7 from the Northern part of Nigeria reported a 
lower percentage (36.2%) of BCG vaccination within 
the first week of life. This difference might be due to a 
lower BCG coverage in the Northern part of Nigeria 
compared to Southern Nigeria, where our study was 
carried out, as shown in the National Demographic 
Health Survey in Nigeria12. 
 
It was observed from this study that birth weight and 
gestational age significantly influenced the age of BCG 
vaccination. These two factors are closely related s pre-
term neonates will most likely have a low birth weight. 
Weight is usually a limitation in the commencement of 
immunization in Nigeria since, from observation in most 
immunization centres, a minimum weight of 2kg is in-
sisted upon by health workers before administration of 
BCG. The same practice of late vaccination of Low birth 
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weight infants have also been reported in Guinea-
Bissau13. According to the World Health Organization, 
pre-term infants in developing countries should be vac-
cinated with BCG at a post-conceptional age of 
40weeks. Since establishing the correct gestational age 
is a challenge in most developing countries, the birth 
weight rather than gestational maturity is utilized in de-
fining when BCG is administered. This has varied impl -
cations for the low birth weight infant, since failure to 
vaccinate children with BCG at birth has been reported 
to contribute to lower BCG vaccination coverage among 
low birth weight children.13Early vaccination of Low 
Birth Weight infants with BCG has also been reported to 
reduce mortality rate by 17% in a randomized control 
trial in Guinea-Bissau14. Late reception of BCG in the 
few patients (1%) reported in Sri Lanka was ascribed to 
illness which resulted in the children being admitted in 
the Special Care Baby Unit11. The gestational age and 
birth weight may be contributory as both are common 
reasons for admission into the neonatal unit. 
 
The prevalence of scar formation from our study indi-
cate that the presence of a BCG scar can be utilized as a 
reliable clinical evidence of BCG vaccination, in the 
absence of immunization card, as most of the studied 
population (96.3%) developed a scar post-vaccinatio. 
This observation is comparable to the findings from Pe-
ru14and India15where the prevalence of scar formation 
was 99% and 90.2% respectively. This observation is, 
however, at variance with the study of Mustapha et l8 in 
Northern Nigeria where the prevalence of scar formation 
was 55.7%. This difference might be accounted for by 
the different age groups in Mustapha’s study and these 
other studies. Mustapha et al studied children betwe n 
the ages of 3 – 59months as against 6weeks – 15months 
in our study, with children between the ages of 6weeks – 
6months forming the bulk (90.7%) of the study popula-
tion. The studies from India and Peru similarly studied 
younger children vaccinated from birth to 3months of 
age and were followed up until 6months.There has been 
documented evidence of waning of BCG scar post-
vaccination in children followed up from infancy to 
fourteen years of age17. The possibility therefore, of dis-
appearance of the BCG scar in the older children among 
the subjects in Mustapha’s study could have contributed 
to the lower prevalence of scar formation reported. 
Other factors which include use of a non-potent vaccine, 
faulty vaccination techniques and lack of maturation of 
the immune system are documented factors that may 
contribute to failure of scar following vaccination15. It is 
difficult to ascertain if these factors contributed to the 
difference in the prevalence of scar formation. 
 
Presence of BCG scar was not significantly affected by 
sex, birth weight, age at vaccination, nutritional status 
and centre of vaccination. Santiago et al15, similarly, did 
not find any association between scar formation and sex, 
birth weight, age at vaccination and nutritional status. 
There was however, a significant association between 
development of BCG scar and gestational age in our 
study, as a higher proportion of the post-term infants 
showed absence of scar post-vaccination. The possible 
reason for this finding is not quite apparent as previous 
studies relating gestational age and scar formation post-
vaccination are at variance. Preterm neonates are mo
likely to show absent scar formation compared to term 
and post-term neonates due to poor immune response as 
reported by Sedaghatianet al18 in the United Arab Emir-
ates. A study in India19 among preterm babies delivered 
less than 35weeks gestation and vaccinated at birth and 
at 38 – 40 weeks post-conception did not show any sta-
tistically significant difference in scar formation. The 
small number of post-term infants in our study may af-
fect the interpretation of this finding and thus affect the 
deductions made. 
 
Limitations of the study  
 
Mothers’ information on birth weight and gestational 
age was utilized in absence of information from the case 






This study shows a high prevalence of BCG scar forma-
tion post vaccination in early childhood and gestational 
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